Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Finch Therapeutics Group Inc.
Headquarters: Somerville, MA, United States of America
Website: http://finchtherapeutics.com...
Year Founded: 2014
Status: Public
Industry Sector: HealthServices
CEO: Matthew P. Blischak
Number Of Employees: 1
Enterprise Value: $10,794,422
PE Ratio: -1.59
Exchange/Ticker 1: Pink:FNCH
Exchange/Ticker 2: N/A
Latest Market Cap: $22,571,800
BioCentury | Oct 25, 2023
Management Tracks
CFO Joanne Bryce to depart Disc
Plus: Jeff Albers joins Scorpion as strategic adviser, and updates from Mironid, 1859, mbiomics and Tevogen
BioCentury | Apr 27, 2023
Management Tracks
BMS’s Caforio to retire as CEO
Plus: Rectify hires Minegishi and updates from Epsilogen, Novo and more
BioCentury | Jan 25, 2023
Regulation
Jan. 24 Quick Takes: FDA panel backs Cidara’s rezafungin
Plus: Amid IP issues, Finch sheds staff and updates from CymaBay, Allogene, Lilly
BioCentury | Jan 4, 2023
Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Aug 26, 2022
Product Development
Aug. 26 Quick Takes: Takeda ends Finch deal
Plus 89bio rises on pegozafermin data and expanded label for Incyte’s Pemazyre
BioCentury | Apr 30, 2022
Product Development
April 29 Quick Takes: FDA lifts Finch clinical hold
Plus All Blue makes offer for Zymeworks and updates from Praxis, Innate and CytoTronics
BioCentury | Mar 2, 2022
Product Development
March 1 Quick Takes: Setbacks in C. diff for Pfizer, Finch
Plus Karyopharm tumbles, Epizyme cuts, and updates from Alnylam, Novavax, Gilead and more
BioCentury | Feb 11, 2022
Management Tracks
Silberstein joins GentiBio as CFO
Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more
BioCentury | Dec 21, 2021
Management Tracks
Founder Zang returns to CEO role at I-Mab
Plus: Ho out as CRISPR’s head of R&D, Pfizer’s Hicks named Intellia’ CBO and more
BioCentury | Sep 9, 2021
Management Tracks
Hayes joins Fulcrum as chief commercial officer
Plus: ImmunityBio, Finch, Rhythm, Infinity, Locanabio and more
Items per page:
1 - 10 of 25